✦ LIBER ✦

MP34-14 TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR USING PHOTOIMMUNOTHERAPY IN THE TREATMENT OF BLADDER CANCER

✍ Scribed by Brancato, Sam; Agarwal, Piyush

Book ID: 122313870
Publisher: Lippincott Williams and Wilkins
Year: 2014
Tongue: English
Weight: 163 KB
Volume: 191
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2014.02.1027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Targeting the Epidermal Growth Factor Re

Targeting the Epidermal Growth Factor Receptor in Bladder Cancer

✍ Weintraub, Michael D. 📂 Article 📅 2013 🏛 OMICS Publishing Group ⚖ 655 KB

Targeting the Epidermal Growth Factor Re

Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer

✍ Dr Robert B. Diasio, Jeanne Fourie 📂 Article 📅 2006 🏛 Springer International Publishing AG 🌐 English ⚖ 205 KB

Epidermal Growth Factor Receptor Targeti

Epidermal Growth Factor Receptor Targeting of Replication Competent Adenovirus Enhances Cytotoxicity in Bladder Cancer

✍ van der Poel, H.G.; Molenaar, B.; van Beusechem, V.W.; Haisma, H.J.; Rodriguez, 📂 Article 📅 2002 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 982 KB

Targeting Epidermal Growth Factor Recept

Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer

✍ Mok, Tony S.K.; Lee, Kirsty; Leung, Linda 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 195 KB

Epidermal Growth Factor Receptor and Oth

Epidermal Growth Factor Receptor and Other Molecular Targets in the Treatment of Cancer

✍ Chris H. Takimoto 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 47 KB

Targeting the epidermal growth factor re

Targeting the epidermal growth factor receptor by erlotinib (Tarceva™) for the treatment of esophageal cancer

✍ Andreas P. Sutter; Michael Höpfner; Alexander Huether; Kerstin Maaser; Hans Sche 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 370 KB 👁 1 views

## Abstract Esophageal cancer is the sixth most common cause of cancer‐related death worldwide. Because of very poor 5‐year survival new therapeutic approaches are mandatory. Erlotinib (Tarceva™), an inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR‐TK), potently suppresses the gr